The first case report of non-nosocomial healthcare-associated infective endocarditis due to methicillin-resistant Staphylococcus aureus USA400 in Rio de Janeiro, Brazil

P V Damasco; F S Cavalcante; R C Chamon; D C Ferreira; S S Rioja; M V Potsch; M P Pastura; V D Marques; M B Castier; E A Marques; K R N Santos

doi:10.1007/s15010-013-0430-2

The first case report of non-nosocomial healthcare-associated infective endocarditis due to methicillin-resistant Staphylococcus aureus USA400 in Rio de Janeiro, Brazil

Infection. 2013 Aug;41(4):851-4. doi: 10.1007/s15010-013-0430-2. Epub 2013 Mar 2.

Authors

P V Damasco¹, F S Cavalcante, R C Chamon, D C Ferreira, S S Rioja, M V Potsch, M P Pastura, V D Marques, M B Castier, E A Marques, K R N Santos

Affiliation

¹ Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.

PMID: 23456477
DOI: 10.1007/s15010-013-0430-2

Abstract

Staphylococcus aureus is the main causal pathogen of infective endocarditis (IE), which may have distinct origins, namely, community, nosocomial, or non-nosocomial healthcare-associated (NNHCA). We report the first case of NNHCA-IE caused by methicillin-resistant S. aureus strain USA400/SCCmec IV in which the combination therapy of rifampin and vancomycin had a favorable outcome for the patient.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-Bacterial Agents / administration & dosage
Brazil
Echocardiography, Transesophageal
Endocarditis / diagnosis*
Endocarditis / drug therapy
Endocarditis / microbiology
Endocarditis / pathology
Genotype
Health Facilities
Humans
Male
Methicillin-Resistant Staphylococcus aureus / isolation & purification*
Molecular Typing
Rifampin / administration & dosage
Staphylococcal Infections / diagnosis*
Staphylococcal Infections / drug therapy
Staphylococcal Infections / microbiology
Staphylococcal Infections / pathology
Treatment Outcome
Vancomycin / administration & dosage

Substances

Anti-Bacterial Agents
Vancomycin
Rifampin